We are live on ! Find out more
MACK

Merrimack Pharmaceuticals, Inc.
MACK

Delisted

MACK was delisted on the 17th of May, 2024.

Back to rankings

1 hedge funds and large institutions have $0 invested in Merrimack Pharmaceuticals, Inc. in 2025 Q1 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% less funds holding

Funds holding: 2 → 1 (-1)

100% less capital invested

Capital invested by funds: $371K → $0 (-$371K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

Holders
1
Holders Change
-1
Holders Change %
-50%
% of All Funds
0.01%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter

MACK Hedge Fund Activity: Q1 2025 in Review

1 of the 7,472 institutional investors tracked by Wall St. Rank reported a position in Merrimack Pharmaceuticals, Inc. (MACK) for Q1 2025, worth a combined $0 — down 100% from $371K a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of MACK and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.

  • 1 institutional investor held Merrimack Pharmaceuticals, Inc. (MACK) as of Q1 2025, down from 2 in Q4 2024.
  • Funds reported $0 of Merrimack Pharmaceuticals, Inc. stock for Q1 2025, down 100% quarter-over-quarter.
  • 0 funds opened new Merrimack Pharmaceuticals, Inc. positions in Q1 2025 and 1 closed out, a net change of -1 holder.

Based on aggregated 13F filings for Q1 2025.